Pancreatic Cancer Research

ResearcherVeterans Health AdministrationNo recent work listed

Jerome Carl Landry

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5113139310. Sources: OpenAlex.

Their work

Papers
18 (first author 1, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
23
Papers, trials and grants by year

2013: 5 papers · 2014: 5 papers · 2015: 2 papers · 2016: 3 papers · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper

Papers 18

  1. Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer. Co-author DOI 10.1002/ijc.32227↗
  2. Chemotherapy with or Without Definitive Radiation Therapy in Inoperable Pancreatic Cancer. Co-author DOI 10.1245/s10434-017-6322-4↗
  3. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radia… Last author DOI 10.1002/cncr.30706↗
  4. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib. Co-author DOI 10.1016/j.ejca.2015.10.057↗
  5. A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458). Co-author DOI 10.1016/j.ijrobp.2016.05.010↗
  6. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer. Co-author DOI 10.1634/theoncologist.2015-0316↗
  7. Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. Last author DOI 10.1002/jso.23921↗
  8. High nuclear hypoxia-inducible factor 1 alpha expression is a predictor of distant recurrence in patients with resected pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ijrobp.2014.11.004↗
  9. Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. Last author DOI 10.1002/cncr.28530↗
  10. Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer. Co-author DOI 10.1038/onc.2013.488↗
  11. CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-13-1996↗
  12. Current controversies in the stage-specific multidisciplinary management of pancreatic cancer. First author DOI 10.14694/edbook_am.2014.34.e157↗
  13. The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. Last author DOI 10.1016/j.ijrobp.2013.06.803↗
  14. The influence of adjuvant radiotherapy dose on overall survival in patients with resected pancreatic adenocarcinoma. Last author DOI 10.1002/cncr.28047↗
  15. Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.28144↗
  16. Tumor size on abdominal MRI versus pathologic specimen in resected pancreatic adenocarcinoma: implications for radiation treatment planning. Last author DOI 10.1016/j.ijrobp.2012.11.019↗
  17. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Co-author DOI 10.1097/mpa.0b013e31829e2006↗
  18. Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the national cancer data base. Co-author DOI 10.1245/s10434-013-3047-x↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bassel F. El‐Rayes · 11 shared papers, 2013–2019 · strength 0.63
  2. David A. Kooby · 13 shared papers, 2013–2018 · strength 0.58
  3. Shishir Kumar Maithel · 9 shared papers, 2013–2018 · strength 0.44
  4. William Adrian Hall · 8 shared papers, 2013–2017 · strength 0.31
  5. Walid Labib Shaib · 4 shared papers, 2016–2019 · strength 0.31
  6. Lauren Elizabeth Colbert · 8 shared papers, 2013–2015 · strength 0.29
  7. Theresa Wicklin Gillespie · 5 shared papers, 2013–2017 · strength 0.23
  8. Ganji Purnachandra Nagaraju · 3 shared papers, 2014–2019 · strength 0.22
  9. Joseph Lipscomb · 4 shared papers, 2013–2014 · strength 0.16
  10. Pretesh R Patel · 2 shared papers, 2017–2018 · strength 0.15
  11. Jim Zhong · 2 shared papers, 2017–2018 · strength 0.15
  12. Volkan N. Adsay · 4 shared papers, 2013–2015 · strength 0.14
  13. Burcu Saka · 4 shared papers, 2013–2015 · strength 0.14
  14. Walter John Curran · 4 shared papers, 2013–2015 · strength 0.14
  15. Gregory B. Lesinski · 1 shared paper, 2019 · strength 0.11
  16. David S. Yu · 3 shared papers, 2013–2014 · strength 0.09
  17. Natalyn Nicole Hawk · 2 shared papers, 2013–2016 · strength 0.09
  18. Juan Manuel Sarmiento · 2 shared papers, 2013–2016 · strength 0.09
  19. Ronica H. Nanda · 1 shared paper, 2015 · strength 0.07
  20. Matthew H. G. Katz · 1 shared paper, 2014 · strength 0.07
  21. Hedy Lee Kindler · 1 shared paper, 2014 · strength 0.07
  22. Olatunji Boladale Alese · 1 shared paper, 2016 · strength 0.06
  23. Hemchandra Mahaseth · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.